Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.46 |
| ▸ | GRN | P28799 | 3/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | LAP3 | P28838 | 3/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24764840 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL22059699 | 0.85 | ALDH1A1 (0.37) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL22060164 | 0.85 | ALDH1A1 (0.37) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL24765346 | 0.82 | MME (0.47) | MAPTGRNSORT1MME | |
| SCHEMBL22060202 | 0.82 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL22060198 | 0.82 | ALDH1A1 (0.35) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL24765392 | 0.81 | CA2 (0.50) | MAPTMME | |
| SCHEMBL26079410 | 0.80 | ALDH1A1 (0.60) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL20734730 | 0.79 | ALDH1A1 (0.55) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL22517730 | 0.79 | ALDH1A1 (0.58) | ALDH1A1MEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ALDH1A1 4110/4885MEN1 1147/4885LMNA 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.